###### Strengths and limitations of this study

-   The results of this study can be generalised to similar settings in other countries in sub-Saharan Africa.

-   The study was cross-sectional and so causal relationships cannot be established.

-   The sample size was small for assessing factors associated with hyponatraemia and therefore weak associations may have been missed.

-   Blood pressure measurements were taken only once, and so patients may have been misclassified as having hypertension.

Introduction {#s1}
============

Heart failure is becoming more common in sub-Saharan Africa due to the epidemiological transition to non-communicable diseases, and the increasing numbers of older people. The population of people aged 60 years and over is increasing in Uganda.[@R1] [@R2] Heart failure is a common observed health problem among older people in Uganda and elsewhere in sub-Saharan Africa, and is believed to be mainly caused by dilated cardiomyopathy, rheumatic heart disease, and hypertension.[@R3]

Older people are particularly sensitive to the development of various electrolyte abnormalities, especially hyponatraemia, which is a serum sodium level below 135 mmol/L.[@R4] [@R5] Serum sodium falls by about 1 mmol/L with each decade increase in age.[@R6] Globally, 18--27% of all patients admitted to hospital with heart failure have hyponatraemia.[@R7] [@R8] As heart failure involves fluid retention in the body, it may lead to dilution hyponatraemia. In heart failure, diuretics normally are used to induce negative balance of sodium. Hyponatraemia is a potent predictor of poor outcome among older inpatients with heart failure.[@R9] There is limited data on the burden of hyponatraemia and its complications in patients with heart failure in sub-Saharan Africa. To the best of our knowledge, the prevalence and factors associated with hyponatraemia among older adults with heart failure have not been studied in Uganda or any other sub-Saharan African countries.

Materials and methods {#s2}
=====================

We conducted a cross-sectional study between August 2013 and March 2014 to determine the prevalence of and factors associated with hyponatraemia among patients aged 60 years and above with heart failure. Patients were eligible for inclusion if they were: aged 60 years and above with a clinical diagnosis of either new onset (acute) or worsening (chronic) heart failure according to the Framingham criteria.[@R10] Patients who could not follow the study procedures were excluded. We consecutively recruited 211 patients with predominately acute decompensated heart failure from the cardiac clinics and wards of Mulago National Referral Hospital and Uganda Heart Institute. Patients were considered to have decompensated heart failure if they had either two major or one major and two minor criteria present concurrently.[@R10] The major criteria we considered in our study were: rales, neck vein distension, hepatojugular reflux, third heart sound and paroxysmal nocturnal dyspnoea. The minor criteria were: bilateral ankle oedema, nocturnal cough, hepatomegaly, dyspnoea on exertion and tachycardia. Both study sites are within the same location in the northeast of Kampala, the capital city of Uganda. Mulago National Referral Hospital is a public hospital offering services at no cost, and has the largest bed capacity in the country with about 1500 beds. The Uganda Heart Institute is an autonomous institution that offers private services to both adult and paediatric patients with heart conditions. It has a bed capacity of about 40 beds.

We informed all eligible patients about the study and the procedures involved; if they agreed to participate, we asked them to sign a consent form. We then ascertained the sociodemographic and clinical characteristics of the patients with a written questionnaire completed by the principal investigator or research assistant. The patients were specifically asked if their doctor had ever told them that they had diabetes mellitus, stroke, chronic kidney disease or hypertension. The care taker was asked of any recent behavioural changes in the patient, and the history was taken of current or previous medication use by the patient. A physical examination was carried out to ascertain weight, height, presence of pallor, oedema, hepatomegaly, raised jugular venous pressure, rales, gallop rhythm and the level of consciousness (mental alteration) using the Glasgow Coma scale. Blood pressures of patients were taken using a manual sphygmomanometer in either the lying down or sitting position depending on the functional status of the patient. Hypertension was defined as systolic blood pressure above 140 mm Hg and/or diastolic blood pressure above 90 mm Hg.

Patients who met the study inclusion criteria fasted overnight, and at least 8 h and 2 mL of venous blood was withdrawn the next morning for measurement of sodium, chloride, potassium, sugar, lipids, creatinine and urea. The blood samples were centrifuged then mounted into the Cobas Integra 400 plus machine manufactured by Roche and analysed the same day in an accredited laboratory. A morning urine sample was collected for measurement of sodium, protein, sugar and presence of casts and red blood cells. Plasma and urine osmolality were calculated from the values obtained using the following formula:

Calculated osmolality=2 Na+ (serum/urine)+Glucose (blood/urine)+Urea (all in mmol/L).

Glomerular filtration rate (GFR) (mL/min/1.73 m^2^) was calculated using Cockcroft-Gault formula: estimated GFR=(140−Age)× weight (kilogram)×0.85 (in females)/serum creatinine (mg/dL)×72.

Chronic kidney disease was classified as: stage 1 GFR \>90, stage 2 GFR 60--89, stage 3 GFR 30--59, stage 4 GFR 15--29 and stage 5 GFR \<15. Most of the patients in this study had been previously hospitalised, and had had echocardiograms done; however, our study mainly focused on clinical diagnosis of heart failure using Framingham criteria. Given the fact that echocardiography is not readily available in most hospitals in Uganda, we used clinical criteria to increase applicability of the findings to a wide range of settings.

Statistical analysis {#s2a}
--------------------

We used multivariate logistic regression analysis to study associations between predefined risk factors and hyponatraemia. All analyses were performed using STATA V.12.0. Variables with a p value \<0.05 were considered statistically significant. For proportions, the sample size was calculated using the following formula n=N/1+N (e)^2^ proposed by Yamane.[@R11]

Patients or care takers gave written informed consent to participate in the study. If a patient was found to have hyponatraemia, his/her clinician was informed and the patient was managed appropriately.

Results {#s3}
=======

The sociodemographic and clinical characteristics of the 211 patients in the study are shown in [table 1](#BMJOPEN2015009775TB1){ref-type="table"}. The largest group of patients was aged 60--69 years (40.3%). The median (IQR) age of the patients was 70.0 (65--77) years, with the oldest patient being 102 years old. Less than half of the study\'s patients were males (n=81, 38.4%). Most patients had been previously hospitalised for heart failure (n=148, 70.1%) and had presented with worsening symptoms; 63 (29.9%) of the patients were newly diagnosed with heart failure, with symptoms for less than a month. More than half (n=134, 63.5%) of the patients were New York Heart Association (NYHA) class 2. Few of the patients (n=52/211, 24.6%) had smoked tobacco, and 90 (42.7%) consumed alcohol at least occasionally. Forty-six study patients had high fasting blood sugar (21.8%), and only one had high triglycerides.

###### 

Sociodemographic and clinical characteristics of the study patients by serum sodium level

                                            Serum sodium level                
  ---------------------------- ------------ -------------------- ------------ -------
  Age group (years)                                                           0.828
   60--69                      85 (40.3)    20 (23.5)            65 (74.5)    
   70--79                      84 (39.8)    22 (26.2)            62 (73.8)    
   ≥80                         42 (19.9)    9 (21.4)             33 (78.6)    
  Sex                                                                         0.602
   Female                      130 (61.6)   33 (25.4)            97 (74.6)    
  Smoking                                                                     0.364
   Yes                         52 (24.6)    15 (28.8)            37 (71.2)    
  Salt intake                                                                 0.056
   Yes                         192 (91.0)   43 (22.4)            149 (77.6)   
  BMI, n=151                                                                  0.283
   Underweight                 18 (11.9)    4 (22.2)             14 (77.8)    
   Normal                      87 (57.6)    19 (21.8)            68 (78.2)    
   Overweight                  34 (22.5)    3 (8.8)              31 (91.2)    
   Obesity                     12 (8.0)     1 (8.3)              11 (91.7)    
  NYHA                                                                        0.005
   Class 1                     1 (0.5)      1 (100.0)            0 (0.0)      
   Class 2                     134 (63.5)   23 (17.2)            111 (82.8)   
   Class 3                     70 (33.2)    24 (34.3)            46 (65.7)    
   Class 4                     6 (2.8)      3 (50.0)             3 (50.0)     
  Diabetes mellitus                                                           0.120
   Yes                         20 (9.5)     2 (10.0)             18 (90.0)    
  Hypertension n=207                                                          0.024
   Yes                         145 (70.1)   28 (19.3)            117 (80.7)   
  Stroke                                                                      0.955
   Yes                         8 (3.8)      2 (25.0)             6 (75.0)     
  Chronic kidney disease                                                      0.782
   Yes                         7 (3.3)      2 (28.6)             5 (71.4)     
  Seizures                                                                    0.223
   Yes                         4 (1.9)      2 (50.0)             2 (50.0)     
  Falls                                                                       0.012
   Yes                         16 (7.6)     8 (50.0)             8 (50.0)     
  Vomiting                                                                    0.006
   Yes                         39 (18.5)    16 (41.0)            23 (59.0)    
  Body weakness                                                               0.224
   Yes                         184 (87.2)   47 (25.5)            137 (74.5)   
  Medication history n=210                                                    
  ACEi/ARB                                                                    0.510
   Yes                         111 (52.9)   29 (26.1)            82 (78.9)    
  Psychotropics                                                               0.421
   Yes                         2 (1.0)      0 (00.0)             2 (100.0)    
  Thiazides diuretics                                                         0.730
   Yes                         22 (10.5)    6 (27.3)             16 (72.7)    
  Loop diuretics                                                              0.013
   Yes                         134 (63.8)   40 (29.9)            94 (70.1)    
  Potassium sparing diuretic                                                  0.069
   Yes                         36 (17.1)    13 (36.1)            23 (63.9)    

\*χ^2^.

ACEi, ACE inhibitors; ARB, angiotensin 11 receptor blocker; BMI, body mass index; NYHA, New York Heart Association.

Most of the 51 patients with hyponatraemia (n=47, 92.2%) were NYHA classes 2 and 3, which is mild--moderate heart failure, as shown in [table 1](#BMJOPEN2015009775TB1){ref-type="table"}. Very few of the 211 patients in the study presented with clinical characteristics suggestive of hyponatraemia such as seizures (n=4, 1.9%), falls (n=16, 7.6%), abnormal behaviour (n=9, 4.3%), altered mentation (n=26, 12.3%) and vomiting (n=39, 18.5%). Sixteen of the 51 patients with hyponatraemia presented with vomiting and most likely had hypovolaemic hyponatraemia, while the remaining 35 patients had dilutional hyponatraemia.

The majority (n=118, 55.9%) of the 211 study patients were known to have hypertension and 7 were known to have chronic kidney disease (3.3%), as shown in [table 1](#BMJOPEN2015009775TB1){ref-type="table"}. More than three-quarters of the patients were using at least one medicine (n=165, 78.2%), with the majority using loop diuretics (n=134, 81.2%). Forty of the 134 patients (29.9%) using loop diuretics had hyponatraemia. We did not analyse differences among the different loop diuretics. Of the 211 study patients, only 22 (10.5%) used thiazide diuretics; of these, 6 (27.3%) had hyponatraemia. Only two of the study patients used psychotropic drugs (amitriptyline and carbamazepine). More than three-quarters of the study patients (n=192, 91.0%) added salt to their food, and 43 of these patients (22.4%) had hyponatraemia. Most (19, 70.4%) of the patients with hyponatraemia had a normal body mass index which was different from other studies where low body mass index has been associated with hyponatraemia.[@R12]

Among the 211 patients in the study, (n=51, 24.2%) had hyponatraemia with serum sodium below 135 mmol/L. At a serum level of 130 mmol/L and below, the prevalence of hyponatraemia was 11.0% and at a serum sodium level below 125 mmol/L (severe hyponatraemia), the prevalence of hyponatraemia was 5.7%. Of the 51 patients with hyponatraemia, more than half had mild hyponatraemia, serum sodium between 135 and 130 mmol/L (n=27, 52.9%).

Forty-three (93.5%); of the patients with hyponatraemia were losing sodium in their urine but all study patients had normal spot urine osmolality. As shown in [table 2](#BMJOPEN2015009775TB2){ref-type="table"}, according to the calculated Glomerular Filtration Rate, 62.4% of patients (n=98/157) had chronic kidney disease and 31.4% (n=16/51) had hyponatraemia. Many (n=74, 47.1%) of the 157 patients had stage 3 kidney disease. In total, 114 (54.0%) of the study patients had high calculated plasma osmolality; only 4 of these patients had hyponatraemia.

###### 

Unadjusted ORs for associations between sociodemographic, clinical characteristics and hyponatraemia

                       Serum sodium level                                       
  -------------------- -------------------- ------------ ---------------------- ------
  Age (years)                                                                   0.83
   60--69              20 (39.2)            65 (40.6)    1                      
   70--79              22 (43.1)            62 (38.8)    1.15 (0.57 to 2.32)    
   ≥80                 9 (17.7)             33 (20.6)    0.89 (0.36 to 2.16)    
  Sex                                                                           0.60
   Male                18 (35.3)            63 (39.4)    1                      
   Female              33 (64.7)            97 (60.6)    0.84 (0.44 to 1.62)    
  GFR, n=157                                                                    
   Stage 1             5 (17.9)             18 (13.9)    1                      
   Stage 2             7 (25.0)             29 (22.5)    0.87 (0.24 to 3.16)    0.69
   Stage 3             11 (39.3)            63 (48.8)    0.63 (0.19 to 2.05)    
   Stage 4             2 (7.1)              13 (10.1)    0.55 (0.09 to 3.31)    
   Stage 5             3 (10.7)             6 (4.7)      1.80 (0.33 to 9.89)    
  Falls                                                                         0.02
   No                  43 (84.3)            152 (95.0)   1                      
   Yes                 8 (15.7)             8 (5.0)      3.53 (1.25 to 9.97)    
  Altered mentation                                                             0.01
   No                  39 (76.5)            146 (91.3)   1                      
   Yes                 12 (23.5)            14 (8.7)     3.21 (1.37 to 7.49)    
  Abnormal behaviour                                                            0.01
   No                  45 (88.2)            157 (98.1)   1                      
   Yes                 6 (11.8)             3 (1.9)      6.98 (1.68 to 29.01)   
  Salt intake                                                                   0.07
   No                  8 (15.7)             11 (6.9)     1                      
   Yes                 43 (84.3)            149 (93.1)   0.40 (0.15 to 1.05)    
  Vomiting                                                                      0.01
   No                  35 (68.6)            137 (85.6)   1                      
   Yes                 16 (31.4)            23 (14.4)    2.72 (1.30 to 5.70)    
  Diabetes mellitus                                                             0.09
   No                  49 (96.1)            142 (88.7)   1                      
   Yes                 2 (3.9)              18 (11.3)    3.10 (0.69 to 13.87)   
  Stroke                                                                        0.95
   No                  49 (96.1)            154 (96.2)   1                      
   Yes                 2 (3.9)              6 (3.8)      0.95 (0.19 to 4.88)    
  CKD                                                                           0.79
   No                  49 (96.1)            155 (96.9)   1                      
   Yes                 2 (3.9)              5 (3.1)      0.79 (0.15 to 4.20)    
  Loop diuretics                                                                0.01
   No                  11 (21.6)            65 (40.9)    1                      
   Yes                 40 (78.4)            94 (59.1)    2.51 (1.20 to 5.26)    
  Potassium sparing                                                             0.08
   No                  38 (74.5)            136 (85.5)   1                      
   Yes                 13 (25.5)            23 (14.5)    2.02 (0.94 to 4.36)    
  BP, n=207                                                                     0.03
   Normal              21 (42.9)            41 (25.9)    1                      
   High                28 (57.1)            117 (74.1)   0.47 (0.24 to 0.91)    

\*χ^2^.

BP, blood pressure; CKD, chronic kidney disease; GFR, glomerular filtration rate.

The statistically significant factors associated with hyponatraemia were use of loop diuretics (OR=2.51, 95% CI 1.20 to 5.26, p=0.01), vomiting (OR=2.72, 95% CI 1.30 to 5.70, p=0.01), falls (OR=3.53, 95% CI 1.25 to 9.97, p=0.02), abnormal behaviour (OR=6.98, 95% CI 1.68 to 29.01, p=0.01) and altered mentation (OR=3.21, 95% CI 1.37 to 7.49, p=0.01), as shown in [table 2](#BMJOPEN2015009775TB2){ref-type="table"}. High-blood pressure was associated with a decrease in odds of hyponatraemia (OR=0.47, 95% CI 0.24 to 0.91, p=0.03).

In multivariate analysis, only vomiting (OR=2.94, 95% CI 1.29 to 6.70, p=0.010) and taking loop diuretics (OR=2.71, 95% CI 1.13 to 6.52, p=0.026) were found to be statistically significantly associated with hyponatraemia (see [table 3](#BMJOPEN2015009775TB3){ref-type="table"}). There was also a suggestion (p=0.077) that high-blood pressure was inversely associated with hyponatraemia (OR=0.51, 95% CI 0.25 to 1.07).

###### 

Age and sex-adjusted ORs for characteristics associated with hyponatraemia

  Characteristic        Adjusted OR (95% CI)   p Value\*
  --------------------- ---------------------- -----------
  Vomiting              2.94 (1.29 to 6.70)    0.010
  Falls                 2.45 (0.72 to 8.38)    0.153
  Altered mentation     1.91 (0.65 to 5.60)    0.336
  Abnormal behaviour    3.44 (0.59 to 20.18)   0.171
  Loop diuretics        2.71 (1.13 to 6.52)    0.026
  Potassium sparing     1.46 (0.61 to 3.49)    0.390
  High-blood pressure   0.51 (0.25 to 1.07)    0.077

\*χ^2^.

Discussion {#s4}
==========

In the past, heart failure was an uncommon condition among older people in sub-Saharan Africa because of low life expectancy and low prevalence of non-communicable diseases. Life expectancy has now improved with more people living past 60 years of age. We were, therefore, able to collect a large sample size of 211 older patients with heart failure in one large hospital in Uganda in the short period of 7 months.

The results of our study show a relatively high prevalence of hyponatraemia (24.2%) in Uganda among patients aged 60 years and above, with mainly mild to moderate heart failure NYHA classes 2 and 3. This finding is different from previous studies carried out in developed countries where hospitalised older patients had a much lower prevalence of hyponatraemia ranging from 7% to 12%.[@R4] [@R13] Hyponatraemia is a marker of poor prognosis for heart failure and is associated with longer hospital stays, and high inhospital and early postdischarge mortality.[@R14] To the best of our knowledge, there have been no other studies of hyponatraemia among patients with heart failure in sub-Saharan Africa.

Low salt intake predisposes to hyponatraemia. In our study, nearly all patients (91.0%) added salt to their food. In other studies it been found that some older people add very little salt to their food, predisposing them to hyponatraemia.[@R17] Patients with hyponatraemia in our study were more likely to present with altered mentation, abnormal behaviour and falls, as found in studies by Adrogué *et al* and Cumming *et al*.[@R18]

Our study found that many patients presented with generalised body weakness (87.2%), headache (23.2%), altered mentation (12.3%), and vomiting (18.5%). The clinical presentation was similar across all the classes of hyponatraemia (mild, moderate, severe). However, in studies carried out elsewhere, patients with mild hyponatraemia tended to be asymptomatic,[@R21] while those with moderate hyponatraemia tended to have anorexia, nausea, and headache;[@R21] those with severe hyponatraemia had confusion, coma, seizures or death.[@R21] [@R22] These clinical presentations are in keeping with the central nervous system effects of hyponatraemia. In general, older chronically ill patients with hyponatraemia develop more symptoms than younger otherwise healthy patients. Symptoms also tend to be more severe when the onset of hyponatraemia is rapid and when the effective plasma osmolality falls to \<240 mOsm/kg. Symptoms of hyponatraemia can be subtle and consist mainly of changes in mental state, including altered personality, lethargy, and confusion. As the serum sodium falls to \<115 mEq/L, stupor, neuromuscular hyperexcitability, hyper-reflexia, seizures and coma occur.[@R23]

The majority of the patients in our study were known to have hypertension (55.9%) which is a similar finding to that in a study conducted by Achadu in Uganda, in 2002 (unpublished data). Most patients (78.2%) in our study were on medication for heart failure, hypertension, and other comorbidities; with the majority using loop diuretics (62.5%) and either ACE inhibitors or Angiotensin 11 receptor blockers (52.9%), which increase sodium loss in urine.

Plasma osmolality, blood pressure, and cardiac output determine the release of vasopressin from the pituitary gland. Vasopressin is a hormone that causes retention of sodium and water. In heart failure, there is inappropriate and continued release of vasopressin due to reduced cardiac output despite a normal or reduced osmolality and this leads to hyponatraemia. Hyponatraemia in heart failure can also be due to maladaptive neurohormonal and renal changes, and diuretic treatment.[@R15] In our study, hyponatraemia was more frequent in patients with renal failure and among those using diuretics.

We found that use of diuretics and vomiting was independently associated with hyponatraemia among older patients with heart failure in Uganda. Use of loop diuretics was the factor most strongly associated with hyponatraemia in our study. This is different from studies in developed countries which have found that thiazides are the diuretic most strongly associated with hyponatraemia.[@R12] [@R15] [@R24] In Uganda, loop diuretics are more commonly used than thiazide diuretics for symptom relief in patients with heart failure, both for inpatients and outpatients. This is because loop diuretics are more readily available and more affordable. Loop diuretics act at the ascending loop of Henle of the kidney tubule by inhibiting the sodium-potassium-chloride channel leading to salt wasting, while thiazide diuretics inhibit the sodium-chloride co-transporter at the distal convoluted tubule by blocking sodium re-absorption by the tubular cells. Vomiting was a factor found to be associated with hyponatraemia in our study. This may have been due to other undiagnosed comorbidities like infections or side effects of the drugs the patients were using.

Study limitations {#s4a}
-----------------

A number of potential limitations need to be acknowledged. We used Framingham\'s criteria for the clinical diagnosis of heart failure without echocardiography, and so we were unable to identify patterns of heart failure. The majority of study patients had been previously hospitalised and had had echocardiograms; however, we were unable to perform repeat echocardiograms for this study because of limited availability and very high cost at the study hospital.[@R25] We were also unable to assess fluid intake because the patients used different size containers to drink fluids. Other limitations included the fact: (1) that our study was cross-sectional and so causal relationships cannot be established, and (2) that the sample size was small for assessing factors associated with hyponatraemia and therefore weak associations may have been missed. Finally, blood pressure measurements were taken only once; thus, patients may have been misclassified as having hypertension because of factors like 'white coat' fear or recent caffeine consumption.

Study strength {#s4b}
--------------

We recruited a consecutive series of patients at a large teaching hospital in Uganda. We believe that our results can be generalised to similar settings in other countries in sub-Saharan Africa.

Conclusion {#s5}
==========

Hyponatraemia is a common electrolyte abnormality among older patients in Uganda with mild to moderate heart failure and is strongly associated with use of loop diuretics. Both parenteral and oral loop diuretics are widely used in Uganda for symptom relief in acute decompensated heart failure. They are cheap and available in urban and rural areas of the country.

All older patients with heart failure and other comorbidities should have their serum sodium level monitored to avert the adverse outcomes associated with hyponatraemia. Older patients with heart failure should have health education about fluid restriction. There is a need to carry out a similar study among community-dwelling older adults to determine the prevalence and factors associated with hyponatraemia.
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